[1]
|
G. M. Nazli, M. M. El Bolking and H. M. Khaled, “Bladder Cancer in Africa: Update,” Seminars in Oncology, Vol. 28, No. 2, 2001, pp. 174-178.
doi:/10.1016/S0093-7754(01)90089-2
|
[2]
|
A. Faysal, M. D. Yafi and M. D. Wassim Kassouf, “Radical Cystectomy Is the Treatment of Choice for Invasive Bladder Cancer,” Canadian Urological Association Journal, Vol. 3, No. 5, 2009, pp. 409-412.
|
[3]
|
D. Raghavan and R. Huben, “Management of Bladder Cancer,” Current Problems in Cancer, Vol. 19, No. 1, 1995, pp. 3-63. doi:/10.1016/S0147-0272(07)80002-X
|
[4]
|
A. Choudhury, R. Swindell, J. P. Logue, P. Anthony Elliott, J. E. Livsey, M. Wise, P. Symonds, J. P. Wylie, V. Ramani, V. Sangar, et al., “Phase II Study of Conformal Hypofractionated Radiotherapy with Concurrent Gemcitabine in Muscle-Invasive Bladder Cancer,” Journal of Clinical Oncology, Vol. 29, No. 6, 2011, pp. 733-738.
doi:/10.1200/JCO.2010.31.5721
|
[5]
|
S. Kotwal, A. Choudhury, C. Johnston, et al., “Similar Treatment Outcomes for Radical Cystectomy and Radical Radiotherapy in Invasive Bladder Cancer Treated at a United Kingdom Specialist Treatment Center,” International Journal of Radiation Oncology Biology Physics, Vol. 70, No. 2, 2008, pp. 456-463.
doi:/10.1016/j.ijrobp.2007.06.030
|
[6]
|
J. Dunst, R. Saur, K. M. Schrott, et al., “Organ-Sparing Treatment of Advanced Bladder Cancer: A 10-Year Experience,” International Journal of Radiation Oncology Biology Physics, Vol. 30, No. 2, 1994, pp. 261-266.
|
[7]
|
D. S. Kaufman, W. U. Shipley, P. P. Griffin, N. M. He- ney, A. F. Althausen and J. T. Efird, “Selective Preservation by Combination Treatment of Invasive Bladder Cancer,” The New England Journal of Medicine, Vol. 329, No. 19, 1993, pp. 1377-1382.
doi:/10.1056/NEJM199311043291903
|
[8]
|
M. Housset, C. Maulard, Y. C. Chretien, et al., “Combined Radiation and Chemotherapy for Invasive Transitional-Cell Carcinoma of the Bladder: A Prospective Study,” Journal of Clinical Oncology, Vol. 11, No. 11, 1993, pp. 2150-2157.
|
[9]
|
L. Eapen, D. Stewart, C. Danjoux, P. Genest, N. Futter, et al., “Intraarterial Cisplatin and Concurrent Radiation for Locally Advanced Bladder Cancer,” Journal of Clinical Oncology, Vol. 7, No. 2, 1989, pp. 230-235. doi:/10.1016/j.eururo.2009.01.002
|
[10]
|
A. Stenzl, N. Cowan, M. De Santis, et al., “The Updated EAU Guidelines on Muscle-Invasive and Metastatic Bladder Cancer,” European Urology, Vol. 55, No. 4, 2009, pp. 815-825.
|
[11]
|
H. Von der Maase, L. Sengelov, J. Roberts, et al., “Long-Term Survival Results of a Randomized Trial Comparing Gemcitabine plus Cisplatin, with Methotrexate, Vinblastine, Doxorubicin, plus Cisplatin in Patients with Bladder Cancer,” Journal of Clinical Oncology, Vol. 23, No. 2, 2005, pp. 4602-4608. doi:/10.1200/JCO.2005.07.757
|
[12]
|
V. K. Sangar, C. A. McBain, J. Lyons, et al., “Phase I Study of Conformal Radiotherapy with Concurrent Gemcitabine in Locally Advanced Bladder Cancer,” International Journal of Radiation Oncology Biology Physics, Vol. 61, No. 2, 2005, pp. 420-425.
doi:/10.1016/j.ijrobp.2004.05.074
|
[13]
|
V. K. Sangar, R. Cowan, G. P. Margison, et al., “An Evaluation of Gemcitabines Differential Radiosensitising Effect in Related Bladder Cancer Cell Lines,” British Journal of Cancer, Vol. 90, No. 2, 2004, pp. 542-548. doi:/10.1038/sj.bjc.6601538
|
[14]
|
B. Pauwels, A. E. C. Korst, F. Lardon and J. B. Vermorken, “Combined Modality Therapy of Gemcitabine and Radiation,” The Oncologist, Vol. 10, No. 1, 2005, pp. 34-51. doi:/10.1634/theoncologist.10-1-34
|
[15]
|
V. K. Sangar, C. A. McBain, J. Lyons, V. A. Ramani, J. P. Logue, J. P. Wylie, N. W. Clarke and R. A. Cowan, “Phase I Study of Conformal Radiotherapy with Concurrent Gemcitabine in Locally Advanced Bladder Cancer,” International Journal of Radiation Oncology Biology Physics, Vol. 62, No. 2, 2005, pp. 420-425.
doi:/10.1016/j.ijrobp.2004.05.074
|
[16]
|
E. L. Kaplan and P. Meier, “Nonparametric Estimation from Incomplete Observations,” Journal of American Statistical Association, Vol. 53, No. 282, 1958, pp. 457-481.
doi:/10.2307/2281868
|
[17]
|
Common Toxicity Criteria, Version 3.
http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdf
|
[18]
|
M. A. Aboziada, H. M. Hamza and A. M. Abdlrahem, “Initial Results of Bladder Preserving Approach by Chemo-Radiotherapy in Patients with Muscle Invading Transitional Cell Carcinoma,” Journal of the Egyptian National Cancer Institute, Vol. 21, No. 2, 2009, pp. 167-174.
|
[19]
|
H. Shawky and G. El-Deen, “Initial Results of Retrospective Study: Preoperative Transurethral Excision plus Chemotherapy and Radiation Therapy and Trial of Bladder Preservation,” Journal of the Egyptian National Cancer Institute, Vol. 19, No. 2, 2007, pp. 133-146.
|
[20]
|
W. U. Shipley, D. S. Kaufman, E. Zehr, et al., “Selective Bladder Preservation by Combined Modality Protocol Treatment: Long-Term Outcomes of 190 Patients with Invasive Bladder Cancer,” Urology, Vol. 60, No. 1, 2002, pp. 62-67. doi:/10.1016/S0090-4295(02)01650-3
|
[21]
|
R. Sauer, S. Birkenhake, R. Kuhn, C. Wittekind, K. M. Schrott and P. Martus, “Efficacy of Radiochemotherapy with Platin Derivatives Compared to Radiotherapy Alone in Organ-Sparing Treatment of Bladder Cancer,” International Journal of Radiation Oncology Biology Physics, Vol. 40, No. 1, 1998, pp. 121-127.
doi:/10.1016/S0360-3016(97)00579-8
|
[22]
|
A. Zapatero, C. Martin de Vidales, R. Arellano, et al., “Updated Results of Bladder Sparing Trimodality Approach for Invasive Bladder Cancer,” Urologic Oncology: Seminars and Original Investigations, Vol. 28, No. 4, 2009, pp. 368-374.
|
[23]
|
W. U. Shipley, K. A. Winter, D. S. Kaufman, et al., “Phase III Trial of Neoadjuvant Chemotherapy in Patients with Invasive Bladder Cancer Treated with Selective Bladder Preservation by Combined Radiation Therapy and Chemotherapy: Initial Results of Radiation Therapy Oncology Group 89-03,” Journal of Clinical Oncology, Vol. 16, No. 11, 1998, pp. 3576-3583.
|
[24]
|
D. S. Kaufman, K. A. Winter, W. U. Shipley, et al., “Phase I-II RTOG Study (99-06) of Patients With Muscle-Invasive Bladder Cancer Undergoing Transurethral Surgery, Paclitaxel, Cisplatin, and Twice-daily Radiotherapy Followed by Selective Bladder Preservation or Radical Cystectomy and Adjuvant Chemotherapy,” Urology, Vol. 73, No. 4, 2009, pp. 833-837.
doi:/10.1016/j.urology.2008.09.036
|
[25]
|
F. Arias, M. A. Dominguez, E. Martinez, et al., “Chemoradiotherapy for Muscle Invading Bladder Carcinoma. Final Report of a Single Institutional Organ-Sparing Program,” International Journal of Radiation Oncology Biology Physics, Vol. 47, No. 2, 2000, pp. 373-378.
doi:/10.1016/S0360-3016(00)00444-2
|
[26]
|
C. Rodel, G. G. Grabenbauer, R. Kuhn, et al., “Organ Preservation in Patients with Invasive Bladder Cancer: Initial Results of an Intensified Protocol of Transurethral Surgery and Radiation Therapy plus Concurrent Cisplatin and 5-Fluorouracil,” International Journal of Radiation Oncology Biology Physics, Vol. 52, No. 2, 2002, pp. 1303-1309. doi:/10.1016/S0360-3016(01)02771-7
|
[27]
|
E. Kent, H. Sandler, J. Montie, et al., “Combined-Modality Therapy with Gemcitabine and Radiotherapy as a Bladder Preservation Strategy: Results of a Phase I Trial,” Journal of Clinical Oncology, Vol. 22, No. 13, 2004, pp. 2540-2545. doi:/10.1200/JCO.2004.10.070
|